Inspire Medical Systems, Inc.
INSP- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001609550
No open-market purchases or sales by Inspire Medical Systems, Inc. insiders were filed in the last 90 days; 275 institutions reported holding it in 13F filings for Q2 2026, worth $1.65B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 3, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Feb 8, 2022 |
| Revenue | $912.0M | $802.8M | $624.8M | $407.9M | $233.4M |
| Cost of revenue | $133.2M | $123.0M | $96.6M | $66.1M | $33.3M |
| Gross profit | $778.8M | $679.8M | $528.2M | $341.7M | $200.1M |
| Operating expenses | – | – | $568.5M | $389.3M | $240.0M |
| Research and development | $103.2M | $114.1M | $116.5M | $68.6M | $37.4M |
| Selling, general and administrative | $624.6M | $529.6M | $452.0M | $320.7M | $202.6M |
| Operating income | $51.0M | $36.1M | -$40.3M | -$47.6M | -$39.9M |
| Interest expense | – | – | $0 | $1.68M | $2.13M |
| Income tax | -$79.7M | $4.94M | $1.25M | $613.0K | $72.0K |
| Net income | $145.4M | $53.5M | -$21.2M | -$44.9M | -$42.0M |
| EPS, basic | $4.95 | $1.80 | $-0.72 | $-1.60 | $-1.54 |
| EPS, diluted | $4.89 | $1.75 | $-0.72 | $-1.60 | $-1.54 |
| Weighted shares, basic | 29.4M | 29.8M | 29.3M | 28.1M | 27.3M |
| Weighted shares, diluted | 29.8M | 30.5M | 29.3M | 28.1M | 27.3M |
| Margins and growth | |||||
| Gross margin | 85.4% | 84.7% | 84.5% | 83.8% | 85.7% |
| Operating margin | 5.6% | 4.5% | -6.4% | -11.7% | -17.1% |
| Net margin | 15.9% | 6.7% | -3.4% | -11.0% | -18.0% |
| Revenue growth, year over year | +13.6% | +28.5% | +53.2% | +74.7% | +102.3% |
| Net income growth, year over year | +171.8% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Feb 8, 2022 |
| Cash and equivalents | $104.8M | $150.2M | $185.5M | $441.6M | $214.5M |
| Short-term investments | $203.5M | $295.4M | $274.8M | $9.82M | $0 |
| Accounts receivable | $119.7M | $93.1M | $89.9M | $61.2M | $34.2M |
| Inventory | $145.3M | $80.1M | $33.9M | $11.9M | $17.2M |
| Total current assets | $583.7M | $630.8M | $593.7M | $530.0M | $268.5M |
| Property, plant and equipment | $97.9M | $71.9M | $40.0M | $17.2M | $8.49M |
| Total assets | $907.3M | $808.4M | $676.8M | $564.9M | $295.1M |
| Total current liabilities | $96.1M | $88.5M | $78.1M | $61.2M | $41.3M |
| Long-term debt | – | – | – | – | $24.5M |
| Total liabilities | $126.2M | $118.7M | $104.3M | $68.9M | $66.0M |
| Shareholders' equity | $781.2M | $689.7M | $572.5M | $496.0M | $229.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Feb 8, 2022 |
| Operating cash flow | $117.0M | $130.2M | $24.7M | $11.6M | -$20.1M |
| Capital expenditures | $38.5M | $39.1M | $23.6M | $9.10M | $4.67M |
| Free cash flow | $78.5M | $91.1M | $1.02M | $2.47M | -$24.8M |
| Depreciation and amortization | $14.0M | $6.55M | $2.85M | $1.86M | $1.22M |
| Stock-based compensation | $130.3M | $116.0M | $82.5M | $52.0M | $26.2M |
| Share buybacks | $175.0M | $75.0M | – | – | – |
| Investing cash flow | $21.4M | -$113.1M | -$294.8M | -$19.6M | $29.1M |
| Financing cash flow | -$183.4M | -$52.4M | $13.9M | $235.1M | $14.9M |
| Net change in cash | -$45.3M | -$35.4M | -$256.1M | $227.1M | $23.9M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 14.3% | 14.5% | 13.2% | 12.7% | 11.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 28, 2026 | 29.0M | −0.3% | SEC |
| Jul 30, 2026 | 28.9M | −2.2% | SEC |
| Apr 28, 2026 | 28.8M | −2.3% | SEC |
| Feb 5, 2026 | 28.6M | −3.6% | SEC |
| Oct 29, 2025 | 29.1M | −3.0% | SEC |
| Jul 30, 2025 | 29.6M | −0.8% | SEC |
| Apr 30, 2025 | 29.5M | −0.7% | SEC |
| Feb 3, 2025 | 29.7M | +0.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.